

Supplemental Table S1. Summary of aCGH gains and losses in the 18 MM samples

Case no.	Losses	Gains
1	none	7q, 8q
2	5q, 9, 10, 16	5p
5	none	none
6	none	none
8	none	none
11	9p, 10q, 11p, 14, 16q, X	1q21.1-23.3, 8q, 13
12	none	none
15	none	none
17	none	none
18	none	none
3	none	6p21.2-25.3
4	1p21.1-36.33/ter, 4p16.3-q25, 5, 6q, 8p23.3-q21.1, 9, 10, 11q, 12q, 15, X	1p21.1-q44/ter, 20
10	none	12q13.2-14.1, 12q15-21.2, 12q24.22-24.23
13	5q23.3-33.2, 8q24.3, 9p21.3, 11q13.2-13.4, 11q21-25/ter, 12q12-13.13, 12q21.2-23.2, 15q11.2-13.3, 17p13.1-13.3, 19	6p21.32-25.3/ter, 7, 15q24.3-26.3/ter, 22q11.21-13.31
14	5p13.2-13.3, 5p14.1-14.3, 5p15.1-15.2, 5p15.2 (2), 5p15.31-15.32, 5q, 9, 10q, 18p, Y	5p11-13.2, 5p13.3-14.1, 5p14.3-15.1, 5p2 (2), 5p15.2-15.31, 5p15.31, 5p15.33, 7q, 20q
16	1p, 4, 9p, 10, 11q14.1-14.3, 11q22.1-25/ter, 14, 17q, 18q, 22q11.23-13.2	11q14.3-22.1, 17p12, 22q11.21-11.23
19	3q13.12-28, 8p, 10	1q, 8q, 12q13.13-14.1, 13q12.11-21.1, 13q31.3-34/ter, 17q11.2-22, 17q22, 17q23.1-25.3/ter, 19p, 19q12-13.32, 22
20	5p13.2-14.3, 5p15.1-15.33, 5q23.2-23.3, 5q31.1, 5q31.2, 5q31.2-32, 5q32, 5q33.3-34, 11q14.2-25/ter, 15q15.1-21.1, 15q23, 15q24.2-25.1, 22q11.23-12.3, 22q13.2, 22q13.31-13.33	1q, 5p13.2, 5p14.3-15.1, 5q23.3-31.1, 5q31.1-31.2, 5q31.2, 5q32, 5q32-33.3, 5q34-35.2, 6p, 7, 15q21.1-23, 15q24.1-24.2, 15q25.1-26.3/ter, 20, 22q12.3-13.2, 22q13.2

good prognosis

poor prognosis

MM, malignant melanoma.